Table 2 Standardised mortality rations (SMR) and absolute excess risks (AER) of 5-year survivors and 10-year survivors of childhood solid tumours according to sex, age at diagnosis, risk group, main diagnostic groups, with corresponding 95% confidence intervals in brackets.
From: Late mortality in survivors of childhood cancer in Hungary
Follow-up period 5–10 yrs | Follow-up period beyond 10 yrs | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Pyrs | Obs | Exp | SMR | AER | Pyrs | Obs | Exp | SMR | AER | |
All patients | 35,006 | 151 | 14.17651 | 10.651 [9.02–12.493] | 39.086 [31.89–46.282] | 63,396 | 145 | 41.41742 | 3.501 [2.954–4.12] | 16.339 [12.118–20.56] |
Males | 19,479 | 79 | 9.750599 | 8.102 [6.414–10.098] | 35.551 [26.072–45.03] | 35,901 | 86 | 31.12748 | 2.763 [2.21–3.412] | 15.284 [9.376–21.193] |
Females | 15,527 | 72 | 4.425912 | 16.268 [12.729–20.487] | 43.52 [32.485–54.556] | 27,495 | 59 | 10.28994 | 5.734 [4.365–7.396] | 17.716 [11.782–23.65] |
Age at diagnosis | ||||||||||
< 1 yr | 4,506 | 4 | 3.742565 | 1.069 [0.291–2.737] | 0.571 [− 11.53–12.675] | 8,316 | 15 | 4.973755 | 3.016 [1.688–4.974] | 12.057 [1.523–22.59] |
1–4 yrs | 9,723 | 37 | 2.361386 | 15.669 [11.032–21.597] | 35.625 [22.978–48.273] | 18,803 | 42 | 8.454915 | 4.968 [3.58–6.715] | 17.84 [10.436–25.245] |
5–9 yrs | 8,819 | 52 | 2.448218 | 21.24 [15.863–27.853] | 56.188 [39.788–72.587] | 16,535 | 39 | 10.6865 | 3.649 [2.833–5.312] | 17.123 [8.768–25.479] |
10–14 yrs | 10,127 | 51 | 4.607548 | 11.069 [8.241–14.553] | 45.811 [31.378–60.243] | 17,197 | 41 | 15.18699 | 2.7 [1.937–3.662] | 15.01 [6.467–23.553] |
15–18 yrs | 1,831 | 7 | 1.016793 | 6.884 [2.768–14.185] | 32.677 [2.369–62.986] | 2,545 | 8 | 2.115251 | 3.782 [1.633–7.452] | 23.123 [− 1.371–47.617] |
Diagnosis period | ||||||||||
1973_79 | 1,798 | 14 | 0.787733 | 17.773 [9.716–29.819] | 73.483 [31.564–115.40] | 6,880 | 28 | 8.773045 | 3.192 [2.121–4.613] | 27.946 [10.671–45.222] |
1980_89 | 8,902 | 47 | 4.760055 | 9.874 [7.255–13.13] | 47.45 [31.61–63.29] | 24,716 | 72 | 18.66532 | 3.857 [3.018–4.858] | 21.579 [14.028–29.13] |
1990_99 | 11,979 | 50 | 4.897524 | 10.209 [7.578–13.46] | 37.651 [25.528–49.774] | 24,345 | 37 | 11.54587 | 3.205 [2.256–4.417] | 10.456 [4.846–16.065] |
2000_08 | 12,327 | 40 | 3.731198 | 10.72 [7.659–14.598] | 29.422 [18.908–39.937] | 7,455 | 8 | 2.43319 | 3.288 [1.419–6.478] | 7.467 [− 1.025–15.959] |
CNS tumours | 10,791 | 67 | 3.646049 | 18.376 [14.241–23.337] | 58.71 [43.444–73.976] | 18,734 | 62 | 11.46761 | 5.407 [4.145–6.931] | 26.974 [18.006–35.941] |
NonCNS tumours | 24,215 | 83 | 10.53046 | 7.882 [6.278–9.771] | 29.928 [22.1–37.755] | 44,662 | 83 | 29.94981 | 2.771 [2.207–3.435] | 11.878 [7.214–16.542] |
HR | 14,934 | 106 | 6.440584 | 16.458 [13.472–19.907] | 66.666 [52.749–80.583] | 26,501 | 80 | 17.29393 | 4.626 [3.668–5.757] | 23.662 [16.367–30.957] |
SR | 20,072 | 47 | 7.735926 | 6.076 [4.464–8.079] | 19.562 [12.337–26.786] | 36,895 | 65 | 24.12348 | 2.694 [2.08–3.434] | 11.079 [6.064–16.094] |
NHL | 3,610 | 6 | 1.465038 | 4.095 [1.503–8.914] | 13.324 [− 1.51–28.158] | 6,322 | 4 | 5.347037 | 0.748 [0.204–1.915] | − 2.131 [− 11.60–7.348] |
Hodgkin | 4,622 | 19 | 1.955754 | 9.715 [5.849–15.171] | 10.406 [− 9.006–29.819] | 8,466 | 32 | 7.103497 | 4.505 [3.081–6.359] | 29.408 [14.93–43.885] |
Astrocytoma | 5,289 | 19 | 1.699856 | 11.177 [6.73–17.455] | 32.71 [15.849–49.57] | 9,725 | 18 | 6.185344 | 2.91 [1.725–4.599] | 12.149 [2.237–22.06] |
Medullobl/PNET | 1,349 | 19 | 0.445332 | 42.665 [25.687–66.626] | 137.54 [73.474–201.61] | 2,070 | 5 | 1.060606 | 4.714 [1.531–11.002] | 19.031 [− 4.279–42.341] |
Ependymoma | 927 | 13 | 0.337685 | 38.497 [20.498–65.832] | 136.59 [59.377–213.81] | 1,621 | 10 | 1.085432 | 9.213 [4.418–16.943] | 54.994 [14.737–95.252] |
CNS other | 1,566 | 6 | 0.532012 | 11.278 [4.139–24.547] | 34.917 [2.929–66.905] | 2,334 | 8 | 1.238838 | 6.458 [2.788–12.724] | 28.968 [3.443–54.493] |
CNS (no hist) | 785 | 5 | 0.328857 | 15.204 [4.937–35.481] | 59.505 [1.868–117.14] | 1,584 | 10 | 1.101806 | 9.076 [4.352–16.691] | 56.175 [14.947–97.404] |
NBLI-II | 2,126 | 1 | 1.219514 | 0.82 [0.021–4.569] | − 1.033 [− 14.76–12.702] | 3,426 | 1 | 1.73673 | 0.576 [0.015–3.208] | − 2.15 [− 11.61–7.314] |
NBLIII-IV | 1,753 | 10 | 0.97946 | 10.21 [4.896–18.776] | 27.438 [− 9.61–64.486] | 3,121 | 10 | 1.583498 | 6.315 [3.028–11.614] | 26.967 [5.594–48.341] |
Retino | 1,466 | 2 | 0.649988 | 3.077 [0.373–11.115] | 9.209 [− 12.55–30.973] | 3,179 | 4 | 1.551672 | 2.578 [0.702–6.6] | 7.702 [− 6.825–22.229] |
Wilms | 3,298 | 7 | 1.096119 | 6.386 [2.568–13.158] | 14.584 [− 2.326–31.494] | 7,005 | 5 | 3.668823 | 1.363 [0.443–3.18] | 1.9 [− 6.338–10.138] |
Primhepatic TU | 490 | 1 | 0.279232 | 3.581 [0.091–19.953] | 14.71 [− 30.53–59.951] | 679 | 0 | 0.350947 | 0 [0–10.511] | − 5.169 [− 22.26–11.932] |
Softtissuesc | 2,283 | 13 | 1.011866 | 12.848 [5.427–19.451] | 21.068 [− 11.06–53.205] | 4,488 | 6 | 3.06223 | 1.959 [0.719–4.265] | 6.546 [− 6.601–19.693] |
Osteosarcoma | 1,565 | 8 | 0.740451 | 10.804 [4.664–21.289] | 46.387 [9.361–83.413] | 2,760 | 11 | 2.127505 | 5.17 [2.581–9.251] | 32.147 [6.417–57.877] |
Ewing | 952 | 10 | 0.364838 | 27.409 [13.144–50.407] | 101.21 [34.927–167.49] | 1,096 | 3 | 0.816056 | 3.676 [0.758–10.744] | 19.926 [− 15.00–54.861] |
Germ cell | 1,113 | 2 | 0.438875 | 4.557 [0.552–16.462] | 14.026 [− 13.47–41.528] | 2,261 | 5 | 1.345693 | 3.716 [1.206–8.671] | 16.162 [− 5.675–37.999] |
Carcinoma | 1,133 | 4 | 0.434283 | 9.211 [2.51–23.583] | 31.471 [− 4.957–67.9] | 1,619 | 3 | 1.143699 | 2.623 [0.541–7.666] | 11.466 [− 13.17–36.109] |